Skip to content
Loop Biz – Lifestyle
Author:
Atrium Therapeutics
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2026